CADTH Canadian Drug Expert Committee recommendation: Ulipristal acetate (Fibristal -- Allergan Inc.) indication: uterine fibroids
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be reimbursed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery, and the intermittent treatment of moderate to severe signs...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
November 2017, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that ulipristal acetate be reimbursed for the treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age who are eligible for surgery, and the intermittent treatment of moderate to severe signs and symptoms of uterine fibroids in adult women of reproductive age, with the duration of each treatment course being three months, if the following conditions are met: Conditions: The patient is under the care of an obstetrician/gynecologist. Treatment should be limited to a maximum of four courses of therapy |
|---|---|
| Item Description: | "Final.". - "This recommendation supersedes the CADTH Canadian Drug Expert Committee (CDEC) recommendation for this drug and indication dated November 15, 2013." |
| Physical Description: | 1 PDF file (8 pages) |